Preventative Cardiology

  • Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics (PopPK) Profile of ABP-745 in Patients with Atherosclerosis. Farhan Katchi, MD. Atom Therapeutics Co., Ltd.
    CURRENTLY ENROLLING
    view on clinicaltrials.org
  • KPL-387-C211:  A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants with Recurrent Pericarditis. Amanda Verma, M.D. Kiniksa Pharmaceuticals, GmBH.
    CURRENTLY ENROLLING
    view on clinicaltrials.org
  • KPL-387-C212: A Phase 2 Posology Study with Long-Term Extension in Participants with Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies. Amanda Verma, M.D. Kiniska Pharmaceuticals, GmBH.
    CURRENTLY ENROLLING
    view on clinicaltrials.org
  • Plaque Characterization using Photon-Counting CT Angiography: A comparison study using conventional energy integrating detector CT and coronary angiography with intravascular imaging. Farhan Katchi, MD. Siemen’s Medical Solutions Inc.
    CURRENTLY ENROLLING
  • PROMPT-LIPID: PRagmatic Trial Of Messaging to Providers about Treatment of HyperLIPIDemia: The PROMPT-Lipid Multicenter Registry Study. Thomas Maddox, M.D. Yale University.
    view on clinicaltrials.org
  • TRANSFORM A: Randomized comparison of Cleerly Coronary Artery Disease Stage-Based Care using Coronary CT angiography vs Risk Factor-Based Care for Primary Prevention of Cardiovascular Events. Farhan Katchi, MD.  Cleerly, Inc. 
    CURRENTLY ENROLLING
    view on clinicaltrials.org
    NCT06112418
  • VICTORION-1-PREVENT: A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients. Farhan Katchi, MD. Novartis.
    view on clinicaltrials.org
  • VICTORION-INCLUSION: Evaluating INClisiran as a soLUtion to improve LDL-C management and cloSe care gaps in an Inclusive ASCVD and ASCVD risk equivalent populatiON(V). Dr. Farhan Katchi, MD. Duke University.
    CLOSED TO ENROLLMENT
    view on clinicaltrials.org